| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC3143 | Lapatinib ditosylate Featured | Lapatinib Ditosylate (GW572016, GW2016, Tykerb, Tyverb) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. |
|
| DC9433 | Lapatinib (ditosylate) | Lapatinib ditosylate(GW-572016 ditosylate) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. |
|
| DC2071 | ABR-215062 (Laquinimod) Featured | Laquinimod (ABR-215062) is a potent immunomodulator. |
|
| DC10853 | LAU159 Featured | LAU159 is a novelα6β3γ2 GABAA receptor inhibitor. |
|
| DC11900 | Lazertinib Featured | Lazertinib (YH25448, GNS-1480) is a highly potent, mutant-selective, irreversible, brain-penetrant and orally active EGFR tyrosine-kinase inhibitors for both the T790M mutation and activating EGFR mutations |
|
| DC7801 | LB-100 Featured | LB-100 is a small-molecular protein phosphatase 2A(PP2A)inhibitor with IC50 of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells. |
|
| DC7707 | LCZ-696 Featured | LCZ696 is a first-in-class dual inhibitor of the angiotensin II receptor(AT II receptor) and neprilysin; a novel single molecule comprising molecular moieties of valsartan and NEP inhibitor prodrug AHU377 (1:1 ratio). |
|
| DC8173 | Lemborexant(E2006) Featured | Lemborexant (E-2006) is a dual antagonist of the orexin OX1 and OX2 receptors which is under development for treatment of insomnia. |
|
| DC12386 | Leniolisib (CDZ173) Featured | Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor currently in phase II/III clinical trials for the treatment of immunodeficiency disorders. |
.gif)
|
| DC7633 | Ligandrol (VK5211, LGD-4033) Featured | Ligandrol (LGD-4033) is a novel nonsteroidal, oral SARM that binds to androgen receptor with high affinity (Ki of 1 nM) and selectivity. |
|
| DC10278 | LGD-6972 Featured | LGD-6972 is a selective and orally active glucagon receptor antagonist. LGD-6972 has the potential for type 2 diabetes research. |
|
| DC7186 | LGK-974 Featured | LGK-974 is a potent and specific PORCN inhibitor, and inhibits Wnt signaling with IC50 of 0.4 nM. |
|
| DC10099 | BGB283 | Lifirafenib（BGB-283） is a Novel potent and selective RAF Kinase and EGFR inhibitor. |
|
| DC1105 | Linagliptin (BI-1356) Featured | Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM. |
|
| DC9123 | Lisinopril Dihydrate | Lisinopril Dihydrate is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks. |
|
| DC10892 | LMI070 (NVS-SM1) Featured | LMI070 (NVS-SM1) is a highly potent, selective and orally active small molecule SMN2 splicing modulator. |
|
| DCAPI1208 | L-NAME HCl | L-NAME is a nonselective inhibitor of nitric oxide synthetases (NOS) for nNOS (bovine), eNOS (human), and iNOS (murine), with Ki of 15 nM, 39 nM and 4.4 μM, respectively. |
|
| DC8907 | Lopinavir Featured | Lopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM,showed potent activity against COVID-19(SARS-COV-2). |
|
| DC9104 | Loratadine | Loratadine(SCH-29851) is a selective inverse peripheral histamine H1-receptor agonist with an IC50 of >32 μM. |
|
| DC8642 | Lorediplon Featured | Lorediplon is a new GABAA modulator Drug for treatment of insomnia. |
|
| DCAPI1419 | Losartan | Losartan is a potent, non peptide antagonist of the angiotensin II receptor type 1. This receptor initiates a signal cascade that causes vasoconstriction. Antagonism of this receptor in turn causes vasodilation by blocking the signal from angiotensin II. |
|
| DC9153 | Losartan Potassium Featured | Losartan is an angiotensin II receptor antagonist, competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. |
|
| DC7711 | Losmapimod Featured | Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3. |
|
| DCAPI1355 | Loteprednol etabonate | Loteprednol etabonate |
|
| DC9837 | Larotrectinib (LOXO-101 sulfate) Featured | LOXO-101 is a small molecule that was designed to block the ATP binding site of the TRK family of receptors, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases. |
|
| DC11448 | LOXO 195(Selitrectinib) Featured | LOXO-195 is a next-generation TRK kinase (TKI) inhibitor, with IC50s of 0.6±0.1 nM, <2.5 nM for TRKA and TRKC respectively. |
|
| DC8541 | ORY-1001(Ladademstat) Featured | ORY-1001 dihydrochloride (RG-6016, Ladademstat) is a highly potent, selective inhibitor of lysine-specific demethylase KDM1A (LSD1) with IC50 of 18 nM, displays high selectivity for KDM1A over other FAD-containing monoamine oxidases. |
|
| DC10755 | LSZ-102 Featured | LSZ102 is a potent, orally bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. |
|
| DC10987 | LTX-315 | This product is discontinued. LTX-315 (Oncopore) is a synthetic 9-mer anticancer peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase-independent necrosis. |
|
| DC11422 | Lumateperone Tosylate Featured | Lumateperone Tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a SERT blocker (Ki = 61 nM). |
|
